All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
214 results for "Gynecologic Cancers" and "Esophagus"
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer
Protocol No
SWOG-S1827
Sub Category
Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability
Protocol No
NRG-CC009
Sub Category
A Phase II/III Study of N-803 (ALT-803) Plus Pembrolizumab Versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)
Testing the Use of Combination Immunotherapy
Treatment (N-803 (ALT-803) plus Pembrolizumab) against the Usual Treatment
for Advanced Non-Small Cell Lung Cancer
Treatment (N-803 (ALT-803) plus Pembrolizumab) against the Usual Treatment
for Advanced Non-Small Cell Lung Cancer
Protocol No
SWOG-S1800D-ALT-803
Sub Category
MRI-ENHANCE MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer
This project is being done to to test an experimental treatment for your rectal adenocarcinoma called Magnetic Resonanceguided Adaptive Radiation Therapy in addition to the standard radiation therapy for your type of cancer.
Protocol No
IIT-HALL-MRI-ENHANCE
Sub Category
Transdermal Buprenorphine for the Treatment of Radiation Induced Mucositis Pain in Head & Neck Cancer Patients: A Pilot Study
Transdermal buprenorphine for the treatment of radiation induced mucositis pain in head & neck cancer patients: A pilot study
Protocol No
IIT-SHREENIVAS-BUPRENORPHINE
Sub Category
A Phase I Study of MR-Guided Dose-Escalated Hypofractionated Adaptive Radiation Therapy and Immunotherapy in Primary Metastatic or Very Locally Advanced Patients with Head and Neck Cancer
A Phase I Study of MR-Guided Dose-Escalated Hypofractionated Adaptive Radiation Therapy and Immunotherapy in Primary Metastatic or Very Locally Advanced Patients with Head and Neck Cancer
Protocol No
IIT-AWAN-NIH-DEHART
Sub Category
A Phase I Dose-Escalation Study of CPI-613 (Devimistat) in Combination with Chemoradiation in Patients with Pancreatic Adenocarcinoma
CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma
Protocol No
IIT-KAMGAR-CPI-613
Sub Category
A Phase 1 Open-label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor alpha (FolRa) Antibody Drug Conjugate (ADC), in Combination with Bevacizumab in Patients with Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers)
STRO-002 With Bevacizumab in Epithelial Ovarian Cancer
Protocol No
SUTRO-STRO-002-GM2
Sub Category
A Phase Ib/II Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
Venetoclax and Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell ALL
Protocol No
ECOG-EA9152-ALL
Sub Category
A First-in-Human, Phase 1-2, Dose Escalation Study of BOXR1030 T Cells in Subjects with Advanced GPC3-Positive Solid Tumors
BOXR1030 T Cells in Advanced GPC3-Positive Solid Tumors
Protocol No
SOTIO-BOXR1030
Sub Category
Risk of Metabolic Adaptation After Weight Loss
The Medical College of Wisconsin is conducting a study to understand how the hormones that control energy expenditure and food intake change during and after weight loss.
Renal Metabolism in Salt-Sensitive Human Blood Pressure
Salt sensitive hypertension is a significant health problem worldwide and a modifiable risk factor for renal, cardiovascular, and cerebrovascular diseases. This study aims to determine how kidney function (by measuring renal oxygenation and blood flow) and the process by which your body converts what you eat and drink into energy food (your metabolism) differs between individuals with and without salt sensitivity. A total of about 70 people between the ages of 25 and 65 with a blood pressure of 110/70 or higher are expected to participate in this at the Medical College of Wisconsin.
Resting Metabolic Rate and Gut Microbiome in Pre-Menopausal Women
The purpose of this study is to better understand how microbes in our gut affect our resting metabolic rate (the amount energy expended at rest by our bodies) and body weight.
A Phase II, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 Tablet in Adult Patients with Advanced Cholangiocarcinoma
Study to Evaluate the Efficacy and Safety of TT-00420 in Cholangiocarcinoma
Protocol No
TRANSTHERA-TT420C1206
Sub Category
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety & Efficacy of Magrolimab vs Placebo in Combination w/ Venetoclax & Azacitidine in Newly Diagnosed, Previously Untreated Patients w/ AML Who Are Ineligible for Intensive Chemotherapy
Magrolimab vs Placebo plus Venetoclax and Azacitidine in AML
Protocol No
GILEAD-GS-US-590-6154-AML
Sub Category
Phase II Randomized Trial of Atezolizumab Versus Atezolizumab and Radiation Therapy for Platinum Ineligible/Refractory Metastatic Urothelial Cancer (ART)
Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer
Protocol No
ALLIANCE-A032002-ART
Sub Category
A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR T Cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
ADP-A2M4 SPEAR T Cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Protocol No
ADP-0044-002-SPEARHEAD-1
Sub Category
A Randomized 3-arm Phase II Study Comparing 1) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR), 2) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients </= 70 Years Old with Untreated Mantle Cell Lymphoma
Comparison of BR/CR, BR/CR-A, and BR-A in patients under 70 with untreated MCL.
Protocol No
ECOG-EA4181-MCL
Sub Category
Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy
Phase III trial to determine if treatment with Sacituzumab Govitecan can prolong survival in patients with non-small cell lung cancer who progressed on standard therapy
Protocol No
GILEAD-GS-US-577-6153
Sub Category
Open-label, Multicenter, Phase 1b Clinical Trial to Evaluate the Safety and Efficacy of Autologous Claudin 18.2 Chimeric Antigen Receptor T-cell Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
Protocol No
CARSGEN-CT041-ST-02
Sub Category